First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G.

被引：2
|
作者：
Papadimitrakopoulou, Vassiliki
Gadgeel, Shirish M.
Borghaei, Hossein
Gandhi, Leena
Patnaik, Amita
Powell, Steven Francis
Gentzler, Ryan D.
Martins, Renato G.
Stevenson, James
Jalal, Shadia Ibrahim
Panwalkar, Amit W.
Yang, James Chih-Hsin
Gubens, Matthew A.
Sequist, Lecia V.
Awad, Mark M.
Fiore, Joseph
Ge, Joy Yang
Raftopoulos, Harry
Langer, Corey J.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Karmanos Canc Inst, Detroit, MI USA
[3] Fox Chase Canc Ctr, Philadelphia, PA USA
[4] Dana Farber Canc Inst, Boston, MA USA
[5] South Texas Accelerated Res Therapeut, San Antonio, TX USA
[6] Univ South Dakota, Sanford Sch Med, Sanford Canc Ctr, Sioux Falls, SD USA
[7] Univ Virginia, Sch Med, Emily Cour Clin Canc Ctr, Charlottesville, VA USA
[8] Seattle Canc Care Alliance, Seattle, WA USA
[9] Cleveland Clin, Cleveland, OH USA
[10] Indiana Univ, Sch Med, Indianapolis, IN USA
[11] Sanford Roger Maris Canc Ctr, Fargo, ND USA
[12] Natl Taiwan Univ Hosp, Taipei, Taiwan
[13] Natl Taiwan Univ Canc Ctr, Taipei, Taiwan
[14] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[15] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA
[16] Harvard Med Sch, Boston, MA USA
[17] Merck & Co Inc, Kenilworth, NJ USA
[18] Abramson Canc Ctr, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.9094
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9094
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC
    Borghaei, H.
    Langer, C. J.
    Gadgeel, S.
    Papadimitrakopoulou, V. A.
    Patnaik, A.
    Powell, S. F.
    Gentzler, R. D.
    Martins, R. G.
    Stevenson, J. P.
    Jalal, S. I.
    Panwalkar, A.
    Yang, J. C-H.
    Gubens, M.
    Sequist, L.
    Awad, M. M.
    Fiore, J.
    Saraf, S.
    Raftopoulos, H.
    Gandhi, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] Pemetrexed-Carboplatin Plus Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC: KEYNOTE-021 Cohort G Update
    Borghaei, H.
    Langer, C.
    Gadgeel, S.
    Papadimitrakopoulou, V.
    Patnaik, A.
    Powell, S.
    Gentzler, R.
    Martins, R.
    Stevenson, J.
    Jalal, S.
    Panwalkar, A.
    Yang, J. C.
    Gubens, M.
    Sequist, L.
    Awad, M.
    Fiore, J.
    Saraf, S.
    Raftopoulos, H.
    Gandhi, L.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1791 - S1791
  • [3] KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC
    Langer, C.
    Gadgeel, S.
    Borghaei, H.
    Patnaik, A.
    Powell, S.
    Gentzler, R.
    Yang, J. C.
    Gubens, M.
    Sequist, L.
    Awad, M.
    Cristescu, R.
    Aurora-Garg, D.
    Albright, A.
    Loboda, A.
    Kobie, J.
    Lunceford, J.
    Ayers, M.
    Lubiniecki, G.
    Piperdi, B.
    Pietanza, M. C.
    Papadimitrakopoulou, V.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S216 - S216
  • [4] Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC
    Awad, Mark M.
    Gadgeel, Shirish M.
    Borghaei, Hossein
    Patnaik, Amita
    Yang, James Chih-Hsin
    Powell, Steven F.
    Gentzler, Ryan D.
    Martins, Renato G.
    Stevenson, James P.
    Altan, Mehmet
    Jalal, Shadia I.
    Panwalkar, Amit
    Gubens, Matthew
    Sequist, Lecia V.
    Saraf, Sanatan
    Zhao, Bin
    Piperdi, Bilal
    Langer, Corey J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : 162 - 168
  • [5] Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G
    Langer, C.
    Gaddgeel, S. M.
    Borghaei, H.
    Papadimitrakopoulou, V. A.
    Patnaik, A.
    Powell, S.
    Gentzler, R. D.
    Martins, R. G.
    Stevenson, J. P.
    Jalal, S. I.
    Panwalkar, A.
    Yang, J. C-H.
    Gubens, M. A.
    Sequist, L. V.
    Awad, M. M.
    Fiore, J. J.
    Ge, Y.
    Raftopoulos, H.
    Gandhi, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] KEYNOTE-021 Cohort G Long-Term Follow-up: First-Line (1L) Pemetrexed and Carboplatin (PC) with or without Pembrolizumab for Advanced Nonsquamous NSCLC
    Awad, M. M.
    Gadgeel, S. M.
    Borghaei, H.
    Patnaik, A.
    Yang, J. Chih-Hsin
    Powell, S. F.
    Gentzler, R. D.
    Martins, R. G.
    Stevenson, J. P.
    Altan, M.
    Jalal, S. I.
    Panwalkar, A.
    Gubens, M.
    Sequist, L. V.
    Saraf, S.
    Zhao, B.
    Piperdi, B.
    Langer, C. J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S8 - S8
  • [7] 24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC.
    Gentzler, Ryan D.
    Langer, Corey J.
    Borghaei, Hossein
    Gadgeel, Shirish M.
    Papadimitrakopoulou, Vassiliki
    Patnaik, Amita
    Powell, Steven Francis
    Martins, Renato G.
    Stevenson, James
    Jalal, Shadia Ibrahim
    Panwalkar, Amit W.
    Yang, James Chih-Hsin
    Gubens, Matthew A.
    Sequist, Lecia V.
    Awad, Mark M.
    Fiore, Joseph
    Saraf, Sanatan
    Keller, Steven M.
    Gandhi, Leena
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer
    Borghaei, Hossein
    Langer, Corey J.
    Gadgeel, Shirish
    Papadimitrakopoulou, Vassiliki A.
    Patnaik, Amita
    Powell, Steven F.
    Gentzler, Ryan D.
    Martins, Renato G.
    Stevenson, James P.
    Jalal, Shadia I.
    Panwalkar, Amit
    Yang, James Chih-Hsin
    Gubens, Matthew
    Sequist, Lecia V.
    Awad, Mark M.
    Fiore, Joseph
    Saraf, Sanatan
    Keller, Steven M.
    Gandhi, Leena
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (01) : 124 - 129
  • [9] Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.
    Gadgeel, Shirish M.
    Stevenson, James
    Langer, Corey J.
    Gandhi, Leena
    Borghaei, Hossein
    Patnaik, Amita
    Villaruz, Liza Cosca
    Gubens, Matthew A.
    Hauke, Ralph J.
    Yang, James Chih-Hsin
    Sequist, Lecia V.
    Bachman, Robert D.
    Ge, Joy Yang
    Raftopoulos, Harry
    Papadimitrakopoulou, Vassiliki
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Pembrolizumab plus Carboplatin and Pemetrexed as 1st-Line Therapy for Advanced Non-Small Cell Lung Cancer: KEYNOTE-021 Cohort G
    Langer, Corey
    Gadgeel, Shirish
    Borghaei, Hossein
    Papadimitrakopoulou, Vassiliki
    Patnaik, Amita
    Powell, Steve
    Gentzler, Ryan
    Martins, Renato
    Stevenson, James
    Jalal, Shadia
    Panwalkar, Amit
    Yang, James Chih-Hsin
    Gubens, Matthew
    Sequist, Lecia
    Fiore, Joseph
    Ge, Joy
    Raftopoulos, Harry
    Gandhi, Leena
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S391 - S392
12345